<DOC>
	<DOCNO>NCT02309593</DOCNO>
	<brief_summary>MicroPort Orthopedics ( MPO ) conduct post market clinical follow-up ( PMCF ) study evaluate safety efficacy total hip arthroplasty ( THA ) resurface component market European Union ( EU ) . These type study require regulatory authority THA resurface device medium long-term clinical evidence available time gain approval market EU . This study design accordance medial device directive ( MEDDEV ) 2.12/2 rev 2 .</brief_summary>
	<brief_title>Post Market Clinical Follow-up Study Protocol PROFEMURÂ® Xm Femoral Stems</brief_title>
	<detailed_description />
	<mesh_term>Joint Diseases</mesh_term>
	<criteria>Subject previously underwent / candidate primary THA following : Noninflammatory degenerative joint disease osteoarthritis , avascular necrosis , ankylosis , protrusio acetabuli , painful hip dysplasia Inflammatory degenerative joint disease rheumatoid arthritis ; Correction functional deformity Subject previously implant / candidate implant specified combination component Subject willing able complete require study visit assessment Not previously implant subject able undergo primary THA procedure Previously implant bilateral subject THAs enrol study provide : specify combination component implanted aspect Inclusion/Exclusion Criteria satisfy enrollment exceed subject count specify Clinical Trial Agreement subject agree second Informed Consent document specific second THA Prospective enrollment previously unimplanted contralateral hip permit study provide : occurs two year index THA specify combination component use aspect Inclusion/Exclusion Criteria satisfy enrollment exceed subject count specify Clinical Trial Agreement subject agree second Informed Consent document specific second THA Subjects skeletally immature ( less 21 year age ) time primary THA surgery Subjects currently enrol another clinical study Subjects unwilling sign Informed Consent document Subjects substance abuse issue Subject incarcerate pending incarceration Subject anticipate require contralateral THA le 1 year index THA enrol hip In addition , previously implant subject exclude meet follow criterion : Subject follow contraindication time implantation Overt infection Distant focus infection ( may cause hematogenous spread implant site ) Rapid disease progression manifest joint destruction bone absorption apparent roentgenogram Inadequate neuromuscular status ( e.g. , prior paralysis , fusion , and/or inadequate abductor strength ) , poor bone stock , poor skin coverage around joint would make procedure unjustifiable Neuropathic joint Hepatitis HIV infection Neurological musculoskeletal disease may adversely affect gait weightbearing</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>avascular necrosis</keyword>
	<keyword>ankylosis</keyword>
	<keyword>protrusio acetabuli</keyword>
	<keyword>painful hip dysplasia</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>correction functional deformity</keyword>
	<keyword>revision procedure</keyword>
</DOC>